{
    "organizations": [],
    "uuid": "92187a897c97e8aae93c9a82fc276de8dfd70071",
    "author": "",
    "url": "https://www.reuters.com/article/brief-amgen-announces-phase-3-xgeva-stud/brief-amgen-announces-phase-3-xgeva-study-results-idUSFWN1PY1PI",
    "ord_in_thread": 0,
    "title": "BRIEF-Amgen Announces Phase 3 Xgeva Study Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Amgen Inc:\n* RESULTS FROM PHASE 3 XGEVAÂ® (DENOSUMAB) STUDY IN PATIENTS WITH MULTIPLE MYELOMA PUBLISHED IN LANCET ONCOLOGY\n* AMGEN INC SAYS SAFETY PROFILE WAS CONSISTENT WITH KNOWN ADVERSE EVENTS OF BOTH XGEVA AND ZOLEDRONIC ACID\n* AMGEN INC SAYS IN THIS STUDY, XGEVA SUCCESSFULLY MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-09T01:57:00.000+02:00",
    "crawled": "2018-02-09T02:18:08.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "amgen",
        "inc",
        "result",
        "phase",
        "denosumab",
        "study",
        "patient",
        "multiple",
        "myeloma",
        "published",
        "lancet",
        "oncology",
        "amgen",
        "inc",
        "say",
        "safety",
        "profile",
        "consistent",
        "known",
        "adverse",
        "event",
        "xgeva",
        "zoledronic",
        "acid",
        "amgen",
        "inc",
        "say",
        "study",
        "xgeva",
        "successfully",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}